A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Actavis Inc.
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Rate and Extend of Absorption
研究概览
简要总结
To compare the rate of absorption and oral bioavailability of a test formulation of Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral dose of the commercially available reference product Atlace® manufactured by Monarch Pharmaceuticals Inc. administrated as a sprinkle on one tablespoonful of applesauce to healthy subjects after a 10-hour overnight fast
详细描述
Study Type: Interventional Study Design: A single-dose, open-label, randomized, two-period crossover study
Official Title: A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
Rate and Extend of Absorption
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must be a male or non-pregnant, non-breast-feeding female.
- •Subject must be between 18 and 55 years of age inclusive.
- •Subject's body weight should be within ±15% of the ideal body weight for their height and estimated frame based on the Metropolitan Life Insurance Company Table.
- •Female subjects of childbearing potential --- not surgically sterile or at least two years postmenopausal-- must agree to utilize one of the following forms of contraception, if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, hormonal (oral, implant, transdermal or injection), double barrier (condom and diaphragm with spermicide), IUD, or vasectomized partner (6 months minimum).
- •Subject must voluntarily consent to participate in this study and provide their written informed consent prior to completion of any study-specific procedures.
- •Subject is willing and able to remain in the research center for the entire duration of each confinement period and return to the research center for any outpatient visits.
排除标准
- •History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic or psychiatric disease or any other condition which, in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
- •Has a clinically significant abnormal finding on the physical exam, medical history or clinical laboratory results at screening.
- •History or presence of allergic or adverse response to the study drug or related drugs.
- •Has been on a significantly abnormal diet during the four weeks preceding the first dose of study medication.
- •Has donated blood or plasma within 30 days prior to the first dose of study medication.
- •Has participated in another clinical trial within 30 days prior to first dose of study medication.
- •Has used any over-the-counter (OTC) medication including vitamins, within 7 days prior to the first dose of study medication.
- •Has used any prescription medication, except hormonal contraceptive or hormonal replacement therapy, within 7 days prior to the first dose of study medication.
- •Has been treated with any known enzyme altering drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
- •Has smoked or used tobacco products within 60 days prior to the first dose of study medication.
- •Has a history of substance abuse (including alcohol) in the past 5 years
- •Is female with a positive pregnancy test.
- •Positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates).
- •Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.
研究组 & 干预措施
A
Ramipril10 mg Capsules, single dose
干预措施: Ramipril10 mg Capsules, single dose (Drug)
B
Atlace® 10 mg capsules, single dose
干预措施: Atlace® 10 mg capsules, single dose (Drug)
结局指标
主要结局
Rate and Extend of Absorption
时间窗: 96 hours
次要结局
未报告次要终点